A systematic literature review of the clinical and socioeconomic burden of bronchiectasis

• Published in: European respiratory review 2024-07, Vol.33 (173), p.240049
• Main Authors: Chalmers, James D, Mall, Marcus A, McShane, Pamela J, Nielsen, Kim G, Shteinberg, Michal, Sullivan, Sean D, Chotirmall, Sanjay H
• Format: Article
• Language: English
• Subjects: Bronchiectasis - diagnosis; Bronchiectasis - economics; Bronchiectasis - epidemiology; Bronchiectasis - mortality; Bronchiectasis - therapy; Cost of Illness; Female; Health Care Costs; Humans; Male; Quality of Life; Reviews; Socioeconomic Factors
• ISSN: 0905-9180; 1600-0617; 1600-0617
• DOI: 10.1183/16000617.0049-2024

The overall burden of bronchiectasis on patients and healthcare systems has not been comprehensively described. Here, we present the findings of a systematic literature review that assessed the clinical and socioeconomic burden of bronchiectasis with subanalyses by aetiology (PROSPERO registration: CRD42023404162). Embase, MEDLINE and the Cochrane Library were searched for publications relating to bronchiectasis disease burden (December 2017-December 2022). Journal articles and congress abstracts reporting on observational studies, randomised controlled trials and registry studies were included. Editorials, narrative reviews and systematic literature reviews were included to identify primary studies. PRISMA guidelines were followed. 1585 unique publications were identified, of which 587 full texts were screened and 149 were included. A further 189 citations were included from reference lists of editorials and reviews, resulting in 338 total publications. Commonly reported symptoms and complications included dyspnoea, cough, wheezing, sputum production, haemoptysis and exacerbations. Disease severity across several indices and increased mortality compared with the general population was reported. Bronchiectasis impacted quality of life across several patient-reported outcomes, with patients experiencing fatigue, anxiety and depression. Healthcare resource utilisation was considerable and substantial medical costs related to hospitalisations, treatments and emergency department and outpatient visits were accrued. Indirect costs included sick pay and lost income. Bronchiectasis causes significant clinical and socioeconomic burden. Disease-modifying therapies that reduce symptoms, improve quality of life and reduce both healthcare resource utilisation and overall costs are needed. Further systematic analyses of specific aetiologies and paediatric disease may provide more insight into unmet therapeutic needs.